1 April 2014
IARC Working Group Report No 7: Primary End-points for Prophylactic HPV Vaccine Trials
The potential of the current licensed preventive virus-like particle human papillomavirus (HPV) vaccines to have a major public health impact is leading to additional clinical trials.
The International Agency for Research on Cancer (IARC)/United States National Cancer Institute (NCI) Expert Meeting of September 2013 brought together a Working Group composed of experts from the non-profit public and academic sectors who possessed a wide range of expertise relevant to HPV vaccines. The Working Group reviewed the scientific evidence as to whether it might be appropriate to use a virological end-point, rather than a disease end-point such as cervical intraepithelial neoplasia of grade 2 or worse (CIN2+), as the primary end-point for some future clinical efficacy trials, and the circumstances under which immunobridging trials might be sufficient for licensure. Virological end-points could accelerate vaccine evaluation and licensure.
The Working Group developed recommendations for clinical trial primary end-points that could also include post-trial follow-up recommendations.
Read the Report
Geographic variation of mutagenic exposures in kidney cancer genomes
Scientists from the International Agency for Research on Cancer (IARC) and partner institutions h...
02.05.2024
Read more
IARC Monographs Volume 134: Aspartame monograph now available
The monograph on aspartame, the first monograph in IARC Monographs Volume 134: Aspartame, Methyle...
29.04.2024
Read more
Launch of CanScreen5 training in francophone African countries
The International Agency for Research on Cancer (IARC) is pleased to announce the launch of the C...
29.04.2024
Read more